Drugs by condition
Drugs approved for myelodysplastic syndromes
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
17
Still marketed, NDA or BLA
Drug classes
7
Novel drugs
10
New molecular entities and new biologics
In development
32
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for myelodysplastic syndromes.
- Grafapex (Treosulfan) · Medexus NovelOrphanJan 21, 2025
- Imkeldi (Imatinib Mesylate) · Shorla Oncology Nov 22, 2024
- Rytelo (Imetelstat Sodium) · Geron NovelOrphanJun 6, 2024
- Alvaiz (Eltrombopag Choline) · Teva Pharms INC Nov 29, 2023
- Inqovi (Cedazuridine, Decitabine) · Taiho Oncology NovelPriority reviewOrphanJul 7, 2020
All approved drugs for myelodysplastic syndromes, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 63 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Nucleoside Metabolic Inhibitor (3)
- Inqovi Cedazuridine, Decitabine · Taiho Oncology · 2020
- Vidaza Azacitidine · Bristol-Myers · 2004
- Azacitidine Azacitidine · Actavis LLC · 2016
Iron Chelator (3)
Erythroid Maturation Agent (1)
- Reblozyl Luspatercept-Aamt · Celgene Corp · 2019
Isocitrate Dehydrogenase 1 Inhibitor (1)
- Tibsovo Ivosidenib · Servier · 2018
Thrombopoietin Receptor Agonist (1)
- Nplate Romiplostim · Amgen · 2008
Thalidomide Analog (1)
- Revlimid Lenalidomide · Bristol Myers Squibb · 2005
Class not listed in FDA's data (7)
- Grafapex Treosulfan · Medexus · 2025
- Rytelo Imetelstat Sodium · Geron · 2024
- Promacta Eltrombopag Olamine · Novartis · 2008
- Imkeldi Imatinib Mesylate · Shorla Oncology · 2024
- Alvaiz Eltrombopag Choline · Teva Pharms INC · 2023
- Promacta Kit Eltrombopag Olamine · Novartis · 2015
- Gleevec Imatinib Mesylate · Novartis · 2003
Drugs in development for myelodysplastic syndromes
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- APG-2575lisaftoclaxPhase 310 trials
Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- AND017Phase 36 trials
Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BL-M11D1Phase 32 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes
- RoxadustatFG-4592, ASP1517Phase 32 trials
Astellas · Chronic Kidney Disease, Renal Anemia, Myelodysplastic Syndromes
- ASTX030cedazuridine + azacitidinePhase 31 trial
Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm
- RimiducidAP1903Phase 23 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- RVU120SEL120Phase 23 trials
Ryvu Therapeutics SA · Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- bexmarilimabFP-1305Phase 22 trials
Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- BLEX 404 LiquidPhase 22 trials
BioLite, Inc. · Myelodysplastic Syndrome (MDS), Triple Negative Breast Cancer
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
- OfirnoflastHT-6184Phase 22 trials
Halia Therapeutics, Inc. · Myelodysplastic Syndromes, Anemia, Myelodysplastic Syndrome
- rivogenlecleucelBPX-501 T cells, BPX-501Phase 22 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- TebapivatAG-946Phase 22 trials
Agios Pharmaceuticals, Inc. · Myelodysplastic Syndromes, Sickle Cell Disease
- AB8939Phase 21 trial
AB Science · Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia
- ABD-3001DIMATEPhase 21 trial
Advanced BioDesign · Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes
- ARD103Phase 21 trial
ARCE Therapeutics, Inc. · Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)
- AZD3632Phase 21 trial
AstraZeneca · Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes
- CFI-400945Phase 21 trial
Treadwell Therapeutics, Inc · Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
1 discontinued brand-name drugs whose label still names it
- Decitabine Decitabine
More on myelodysplastic syndromes: recruiting trials · published research
Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelofibrosis · Sickle cell disease · Hemophilia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.